Phase I Study Protocol for Ex Vivo Lentiviral Gene Therapy for the Inherited Skin Disease,Netherton Syndrome

Abstract

Netherton syndrome (NS) is a serious inherited skin disorder caused by mutations in the serine protease inhibitor Kazal type 5 gene (SPINK5), which encodes for a serine protease inhibitor lymphoepithelial Kazal type-related inhibitor (LEKTI). Patients with NS have defective keratinization, hair shaft defects, recurrent infections, atopy, and a predisposition to skin malignancies. Historically, 1 in 10 infants has died before their first birthday. Currently, there are no proven treatments to cure this condition.

A SIN-lentiviral vector encoding the codon-optimized SPINK5 gene under the control of a 572 bp element derived from the human involucrin promoter can confer compartment-specific LEKTI expression in NS keratinocytes with restoration of normal skin architecture. Here we detail a study protocol for a phase I trial for feasibility and safety evaluations of autologous epidermal sheets generated from ex vivo gene-corrected keratinocyte stem cells, which will be grafted onto patients with mutation-proven NS.

Get full access to this article

View all access options for this article.

References

Aiuti

, et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151.

Biffi

, et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 1233158.

Bitoun

, et al. (2003). LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum. Mol. Genet., 12, 2417–2430.

Bonnart

, et al. (2010). Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest., 120, 871–882.

Briot

, et al. (2009). Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med., 206, 1135–1147.

Cavazza

, and Mavilio

(2012). Gene therapy of skin adhesion disorders (mini review). Curr. Pharm. Biotechnol., 13, 1868–1876.

Cavazzana-Calvo

, et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 467, 318–322.

Chavanas

, et al. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet., 25, 141–142.

Choate

K.A.

, Medalie

D.A.

, Morgan

J.R.

, and Khavari

P.A.

(1996). Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat. Med., 2, 1263–1267.

10.

Deraison

, et al. (2007). LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell, 18, 3607–3619.

11.

W.L.

, et al. (2011). Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther., 19, 408–416.

12.

W.L.

, et al. (2012). Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression. Hum. Gene Ther., 23, 83–90.

13.

Egelrud

, et al. (2005). hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br. J. Dermatol., 153, 1200–1203.

14.

Fenjves

E.S.

, Yao

S.N.

, Kurachi

, and Taichman

L.B.

(1996). Loss of expression of a retrovirus-transduced gene in human keratinocytes. J. Invest. Dermatol., 106, 576–578.

15.

Gagnoux-Palacios

, et al. (2005). Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J. Gene Med., 7, 1178–1186.

16.

Gerrard

A.J.

, Hudson

D.L.

, Brownlee

G.G.

, and Watt

F.M.

(1993). Towards gene therapy for haemophilia B using primary human keratinocytes. Nat. Genet., 3, 180–183.

17.

Ghazizadeh

, Doumeng

, and Taichman

L.B.

(2002). Durable and stratum-specific gene expression in epidermis. Gene Ther., 9, 1278–1285.

18.

Hacein-Bey-Abina

, et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415–419.

19.

Hacein-Bey-Abina

, et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118, 3132–3142.

20.

Hernon

C.A.

, et al. (2006). Clinical experience using cultured epithelial autografts leads to an alternative methodology for transferring skin cells from the laboratory to the patient. Regen. Med., 1, 809–821.

21.

Howe

S.J.

, et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118, 3143–3150.

22.

Jayakumar

, et al. (2004). Expression of LEKTI domains 6–9′ in the baculovirus expression system: recombinant LEKTI domains 6–9′ inhibit trypsin and subtilisin A. Protein Expr. Purif., 35, 93–101.

23.

Komatsu

, et al. (2002). Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol., 118, 436–443.

24.

Kuhn

, et al. (2002). In vivo assessment of gene delivery to keratinocytes by lentiviral vectors. J. Virol., 76, 1496–1504.

25.

MacNeil

(2007). Progress and opportunities for tissue-engineered skin. Nature, 445, 874–880.

26.

Magert

HJ.

, et al. (1999). LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J. Biol. Chem., 274, 21499–21502.

27.

Marchetto

M.C.

, Correa

R.G.

, Menck

C.F.

, and Muotri

A.R.

(2006). Functional lentiviral vectors for xeroderma pigmentosum gene therapy. J. Biotechnol., 126, 424–430.

28.

Mavilio

, et al. (2006). Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med., 12, 1397–1402.

29.

Mitsudo

, et al. (2003). Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry, 42, 3874–3881.

30.

Montini

, et al. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol. Ther., 6, 759–769.

31.

Montini

, et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol., 24, 687–696.

32.

Moustafa

, et al. (2004). A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet. Med., 21, 786–789.

33.

Ott

M.G.

, et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med., 12, 401–409.

34.

Rheinwald

J.G.

(1989). Methods for clonal growth and serial cultuvation of normal human epidermal keratinocytes and mesothelial cells. In A Practical Approach. Baserga

, ed. (IRL Press, Oxford), pp. 81–94.

35.

Sales

K.U.

, et al. (2010). Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat. Genet., 42, 676–683.

36.

Uitto

, Christiano

A.M.

, McLean

W.H.

, and McGrath

J.A.

(2012). Novel molecular therapies for heritable skin disorders. J. Invest. Dermatol., 132, 820–828.

37.

Watt

F.M.

(2002). The stem cell compartment in human interfollicular epidermis. J. Dermatol. Sci., 28, 173–180.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.42 MB